5 Stocks Improving Performance Of The Drugs Industry

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 3 points (0.0%) at 14,544 as of Monday, April 22, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,423 issues advancing vs. 1,490 declining with 125 unchanged.

The Drugs industry currently sits up 0.4% versus the S&P 500, which is up 0.3%. A company within the industry that fell today was Pfizer ( PFE), up 0.45.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry higher today:

5. Biogen Idec ( BIIB) is one of the companies pushing the Drugs industry higher today. As of noon trading, Biogen Idec is up $9.93 (4.89) to $213.20 on heavy volume Thus far, 1.7 million shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $204.36-$214.13 after having opened the day at $204.86 as compared to the previous trading day's close of $203.27.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $46.9 billion and is part of the health care sector. The company has a P/E ratio of 34.5, above the S&P 500 P/E ratio of 17.7. Shares are up 35.7% year to date as of the close of trading on Friday.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, good cash flow from operations and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Biogen Idec Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

4. As of noon trading, Celgene Corporation ( CELG) is up $4.09 (3.34) to $126.45 on heavy volume Thus far, 2.4 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $123.55-$127.57 after having opened the day at $124.16 as compared to the previous trading day's close of $122.36.

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies to treat cancer and immune-inflammatory related diseases in the United States, Europe, and other countries. Celgene Corporation has a market cap of $49.9 billion and is part of the health care sector. The company has a P/E ratio of 36.1, above the S&P 500 P/E ratio of 17.7. Shares are up 51.8% year to date as of the close of trading on Friday.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $0.36 (0.87) to $41.51 on light volume Thus far, 3.5 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.9 million shares. The stock has ranged in price between $40.95-$41.52 after having opened the day at $41.17 as compared to the previous trading day's close of $41.15.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $66.6 billion and is part of the health care sector. The company has a P/E ratio of 35.0, above the S&P 500 P/E ratio of 17.7. Shares are up 26.3% year to date as of the close of trading on Friday.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Bristol-Myers Squibb Company Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Gilead ( GILD) is up $0.66 (1.25) to $53.83 on heavy volume Thus far, 8.4 million shares of Gilead exchanged hands as compared to its average daily volume of 10.3 million shares. The stock has ranged in price between $53.29-$54.19 after having opened the day at $54.12 as compared to the previous trading day's close of $53.17.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $77.5 billion and is part of the health care sector. The company has a P/E ratio of 31.0, above the S&P 500 P/E ratio of 17.7. Shares are up 38.5% year to date as of the close of trading on Friday.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, increase in net income, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Gilead Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Amgen ( AMGN) is up $1.32 (1.19) to $112.70 on light volume Thus far, 2.0 million shares of Amgen exchanged hands as compared to its average daily volume of 5.4 million shares. The stock has ranged in price between $110.83-$112.82 after having opened the day at $112.01 as compared to the previous trading day's close of $111.38.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $80.5 billion and is part of the health care sector. The company has a P/E ratio of 19.5, above the S&P 500 P/E ratio of 17.7. Shares are up 24.7% year to date as of the close of trading on Friday.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null